The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Bausch + Lomb has abandoned its next great hope in glaucoma after the eye drops flunked a phase 2 study. The eye health company had been evaluating the alpha-2B agonist, dubbed BL1107, in a mid-stage ...

In 2024, Americans reported losing $470 million to scams that started with texts, according to the Federal Trade Commission. Text scams are also becoming harder to detect with AI. Knowing what to look ...

EAST LANSING – For decades, the clock striking noon at IM West on Michigan State University's campus meant sounds of basketballs dribbling and tennis shoes squeaking on the floor of an upstairs ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the release of ...

The third round of the Valspar Championship will tee off Saturday at the Copperhead Course in Palm Harbor, Florida. Sungjae Im leads the field after carding rounds of 64-69. The 27-year-old golfer is ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Yet while recent developments challenge the bull case, the resultant sell-off could work in your favor. If the stock continues to drop, Bausch Health could move to an opportune entry point for a ...

December 11 - Two-time PGA Tour winner Sungjae Im of South Korea denied reports that he is set to move to LIV Golf with a post to social media this week. With multiple reports saying the 2018-19 PGA ...

Korea’s Sungjae Im, a two-time PGA Tour winner and one of the Tour's ironmen, will not leave for the rival circuit, a source tells Sports Illustrated. Sungjae Im is a two-time PGA Tour winner and has ...

Bausch Health has struck a deal to buy Durect for $63 million upfront, landing a phase 3-ready liver disease candidate that the companies believe has blockbuster potential. Durect reported top-line ...